Novavax, Inc. Company Profile | NVAX Company Information

idellecromwell1991.blogspot.com
Novavax, Inc., a Delaware corporation (Novava x or the Company), was incorporated in 1987, and is a clinical-stagew biopharmaceutical company focused oncreating value-added vaccines that improvew upon current preventive options for a range of infectious These vaccines leverage the Companys virus-like-particle platform technology coupled with a unique, disposablre production technology. The Company produces these VLP potent, recombinant vaccines utilizing new and efficientmanufacturinfg approaches.
VLPs are genetically engineered three-dimensional nanostructures, which incorporate immunologically important lipids and recombinant Our VLPs resemble the virus but lack the genetif material to replicatethe virus. Our proprietary productiob technology uses insect cells rather then chicken eggs ormammaliaj cells. The Companys current productr targets include vaccines against the H5N1 and other subtypes of avianh influenza withpandemic potential, humanj seasonal influenza, Varicella Zoster (VZV), which causes shingles, and a Respiratorty Syncytial Virus (RSV). We made significany progress since 2007 in our vaccine that targetsx the H5N1 avian influenza withpandemicx potential.
In December we announced favorable interim results for a Phase I clinical trial which began in July 2007 for our pandemixinfluenza vaccine, that demonstrated immunogenicity and ...